High-Coverage Rollout of PReP Tied to Drop in HIV Diagnoses

Share this content:
High-Coverage Rollout of PReP Tied to Drop in HIV Diagnoses
High-Coverage Rollout of PReP Tied to Drop in HIV Diagnoses

FRIDAY, Oct. 26, 2018 (HealthDay News) -- A rapid, targeted, high-coverage rollout of HIV pre-exposure prophylaxis (PrEP) is associated with a decrease in HIV diagnoses among high-risk men who have sex with men (MSM), according to a study published online Oct. 17 in The Lancet.

Andrew E. Grulich, Ph.D., from the University of New South Wales in Australia, and colleagues recruited high-risk gay and bisexual men in a network of 21 clinics in an implementation cohort study of daily co-formulated tenofovir disoproxil fumarate and emtricitabine as HIV PrEP. Protocol-specified co-primary outcomes (within-cohort HIV incidence and change in population HIV diagnoses between the 12-month periods before and after PrEP rollout) were reported 12 months after recruitment of 3,700 participants.

The researchers found that two men became infected with HIV over 4,100 person-years (incidence, 0.048 per 100 person-years); both of the men had been nonadherent to PrEP. In New South Wales, there was a reduction in HIV diagnoses in MSM from 295 in the 12 months before PrEP rollout to 221 in the 12 months after (relative risk reduction, 25.1 percent; 95 percent confidence interval, 10.5 to 37.4 percent). Declines were seen in recent HIV infections (from 149 to 102; relative risk reduction, 31.5 percent; 95 percent confidence interval, 11.3 to 47.3 percent) and in other HIV diagnoses (from 146 to 119; relative risk reduction, 18.5 percent; 95 percent confidence interval, −4.5 to 36.6 percent).

"Rapid, targeted, high-coverage rollout to scale was accompanied by rapid reductions in HIV incidence at the population level," the authors write. "PrEP is a highly effective element of the combination prevention approach in MSM."

Several authors disclosed ties to the pharmaceutical industry, including Gilead Sciences, which partially funded the study.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA: Gout Drug Uloric Increases Risk of Death

FDA: Gout Drug Uloric Increases Risk of Death

Medication is associated with increased risk of heart-related death and death from all causes

Since Early 2000s, Overdose Death Rates Are Highest in U.S.

Since Early 2000s, Overdose Death Rates Are Highest ...

U.S. was not an outlier in terms of drug overdose mortality prior to the early 2000s

National Health Spending Set to Increase 5.5 Percent Annually

National Health Spending Set to Increase 5.5 Percent ...

Long-observed demographic and economic factors expected to drive growth in health spending

is free, fast, and customized just for you!




Already a member?

Sign In Now »